WAKEFIELD, MA, June 4 /CNW/ - NUCRYST Pharmaceuticals Corp. (NASDAQ:
NCST; TSX: NCS) today announced that Edward Gaj Jr. has been appointed Vice
President, Corporate Development. He will be responsible for leading NUCRYST's
corporate partnering initiatives, strategic planning, corporate communications
and patent portfolio management.
"Ed brings a wealth of experience in the pharmaceutical industry and he
will add to the bench strength of our senior management team," said Scott H.
Gillis, President and CEO of NUCRYST. "With his successful track record of
technology and product licensing leading to business growth, he will play a
pivotal role in advancing our partnering initiatives and corporate
Since 1998, Mr. Gaj held a series of progressively senior positions at
Anika Therapeutics including Director and Executive Director, Marketing and
Business Development and most recently, Franchise Director, Aesthetics. Mr.
Gaj has considerable knowledge and experience developing licensing and
commercialization strategies, structuring and negotiating agreements and
running all aspects of a key business unit.
Previously, Mr. Gaj was with B&E Consulting, where he was responsible for
new business opportunity assessment and development for clients. He also held
positions at Immunologic Pharmaceutical Corp, Biogen, Alpha Therapeutics Corp
and Lederle Laboratories. He started his career as an oncology pharmacist at
the New England Deaconess Hospital and a staff pharmacist at the Lahey Clinic.
Mr. Gaj earned a BS and MS at the Massachusetts College of Pharmacy and
is a registered pharmacist.
NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures
and commercializes medical products that fight infection and inflammation
using its patented atomically disordered nanocrystalline silver technology.
Smith & Nephew plc sell a range of advanced wound care products under their
Acticoat(TM) trade mark: Acticoat(TM) products incorporate NUCRYST's
SILCRYST(TM) coatings and are sold in over 30 countries. NUCRYST is also
developing pharmaceutical products to address medical conditions that are
characterized by both infection and inflammation. The company has developed
its proprietary nanocrystalline silver in a powder form for use as an active
pharmaceutical ingredient, referred to as NPI 32101.
Acticoat(TM) is a trademark of Smith & Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
This news release may contain forward-looking statements within the
meaning of securities legislation in the United States and Canada. These
statements are based on current expectations that are subject to risks and
uncertainties, and the Company can give no assurance that these expectations
are correct. Various factors could cause actual results to differ materially
from those projected in such statements, including but not limited to: the
initiation, timing, progress and results of our preclinical and clinical
trials, research and development programs; our ability to implement our
business model and strategic plans for our business, product candidates and
technology; our ability to maintain and establish corporate collaborations;
changes in general economic conditions; financial considerations; other risks
and uncertainties unidentified at this time; and management's response to
these factors. The Company disclaims any intention or obligation to revise
forward-looking statements whether as a result of new information, future
developments or otherwise. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement.
For further information:
For further information: David Wills, (416) 504-8464, email@example.com,